NEW YORK, Oct. 16 – Atugen, a Berlin-based genomics company, said Tuesday it had signed a target validation deal with AstraZeneca.

Under the terms of the deal, Atugen will use its GeneBloc antisense technology to validate targets of interest to the British pharmaceutical company. The companies previously completed a target evaluation deal that dates back to 1999.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.